Clinical Trial Update: A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes an early-phase study of IBI3003 for relapsed or refractory multiple myeloma that is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• IBI3003

Snippet

Sponsor: Fortvita Biologics (USA)Inc. | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING